Cipla Limited (NSE:CIPLA)
1,515.20
+18.80 (1.26%)
Apr 17, 2025, 3:29 PM IST
Cipla Revenue
Cipla had revenue of 69.62B INR in the quarter ending December 31, 2024, with 7.01% growth. This brings the company's revenue in the last twelve months to 267.20B, up 6.39% year-over-year. In the fiscal year ending March 31, 2024, Cipla had annual revenue of 255.37B with 13.20% growth.
Revenue (ttm)
267.20B
Revenue Growth
+6.39%
P/S Ratio
4.58
Revenue / Employee
9.62M
Employees
27,764
Market Cap
1,223.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
Mar 31, 2020 | 170.81B | 7.57B | 4.64% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Fortis Healthcare | 75.61B |
Cipla News
- 1 day ago - Cipla’s Goa unit gets ‘Voluntary Action Indicated’ classification from USFDA after inspection - Business Upturn
- 8 days ago - Cipla in focus after USFDA approves generic version of blockbuster cancer drug Abraxane - Business Upturn
- 8 days ago - Cipla receives USFDA approval for Generic Abraxane - Business Upturn
- 10 days ago - Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’ - Business Upturn
- 13 days ago - Cipla: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern - Business Upturn
- 14 days ago - Nifty 50 top losers today, April 4: Tata Steel, Hindalco Industries, ONGC, Tata Motors, Cipla and more - Business Upturn
- 15 days ago - Cipla shares drop over 6% after Trump hints at pharma tariffs; heavy U.S. exposure adds pressure - Business Upturn
- 15 days ago - Nifty 50 top gainers today, April 3: Power Grid, Sun Pharmaceutical, Cipla, UltraTech and more - Business Upturn